$NVRO
NEVRO CORP

2023 Q2 Form 10-Q Financial Statement

#000095017023014896 Filed on April 26, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $108.8M $96.33M $87.84M
YoY Change 4.41% 9.66% -0.87%
Cost Of Revenue $34.37M $31.70M $28.75M
YoY Change 9.17% 10.27% 9.32%
Gross Profit $74.44M $64.62M $59.09M
YoY Change 2.35% 9.36% -5.15%
Gross Profit Margin 68.42% 67.09% 67.27%
Selling, General & Admin $86.76M $86.19M $79.33M
YoY Change 3.32% 8.66% 8.26%
% of Gross Profit 116.55% 133.37% 134.24%
Research & Development $13.32M $14.76M $12.54M
YoY Change 6.12% 17.7% 8.69%
% of Gross Profit 17.89% 22.83% 21.21%
Depreciation & Amortization $1.671M $1.541M $1.495M
YoY Change 7.05% 3.08% 35.79%
% of Gross Profit 2.24% 2.38% 2.53%
Operating Expenses $100.1M $100.9M $91.86M
YoY Change 3.69% 9.89% 8.32%
Operating Profit -$25.64M -$36.32M -$32.77M
YoY Change 7.77% 10.85% 45.56%
Interest Expense $1.730M $1.613M -$1.460M
YoY Change 7.59% -210.48% -122.3%
% of Operating Profit
Other Income/Expense, Net -$338.0K -$46.00K $85.00K
YoY Change -191.85% -154.12% -118.6%
Pretax Income -$24.25M -$34.70M -$34.14M
YoY Change -2.03% 1.64% 16.93%
Income Tax $477.0K $325.0K $181.0K
% Of Pretax Income
Net Earnings -$24.72M -$35.03M -$34.33M
YoY Change -1.06% 2.05% 16.12%
Net Earnings / Revenue -22.72% -36.36% -39.08%
Basic Earnings Per Share -$0.69 -$0.98 -$0.98
Diluted Earnings Per Share -$0.69 -$0.98 -$978.6K
COMMON SHARES
Basic Shares Outstanding 35.82M 35.54M 35.07M
Diluted Shares Outstanding 35.92M 35.58M 35.07M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $329.9M $341.8M $323.6M
YoY Change 6.15% 5.6% -43.85%
Cash & Equivalents $65.19M $64.23M $50.08M
Short-Term Investments $264.8M $277.5M $274.2M
Other Short-Term Assets $11.92M $14.67M $13.10M
YoY Change -1.14% 12.05% 27.14%
Inventory $120.1M $113.3M $90.59M
Prepaid Expenses
Receivables $69.40M $65.73M $63.05M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $531.3M $535.5M $490.4M
YoY Change 9.94% 9.19% -33.62%
LONG-TERM ASSETS
Property, Plant & Equipment $34.76M $22.91M $20.84M
YoY Change 67.18% 9.95% 36.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.413M $3.109M $5.094M
YoY Change -7.13% -38.97% 15.77%
Total Long-Term Assets $38.17M $38.97M $42.50M
YoY Change -6.02% -8.31% 14.86%
TOTAL ASSETS
Total Short-Term Assets $531.3M $535.5M $490.4M
Total Long-Term Assets $38.17M $38.97M $42.50M
Total Assets $569.5M $574.4M $532.9M
YoY Change 8.7% 7.8% -31.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $30.30M $29.23M $27.14M
YoY Change -3.2% 7.72% -6.75%
Accrued Expenses $45.35M $40.37M $38.33M
YoY Change 24.52% 5.33% -9.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $77.53M $74.92M $70.32M
YoY Change 6.69% 6.53% -71.46%
LONG-TERM LIABILITIES
Long-Term Debt $187.5M $187.2M $186.0M
YoY Change 0.66% 0.66% 29.13%
Other Long-Term Liabilities $9.750M $2.157M $36.22M
YoY Change -55.84% -94.04% 89.61%
Total Long-Term Liabilities $197.2M $189.3M $222.2M
YoY Change -5.33% -14.78% 36.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $77.53M $74.92M $70.32M
Total Long-Term Liabilities $197.2M $189.3M $222.2M
Total Liabilities $274.8M $273.2M $292.5M
YoY Change -6.52% -6.6% -28.57%
SHAREHOLDERS EQUITY
Retained Earnings -$667.0M -$642.2M
YoY Change -0.38%
Common Stock $963.6M $945.5M
YoY Change 6.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $294.8M $301.2M $240.4M
YoY Change
Total Liabilities & Shareholders Equity $569.5M $574.4M $532.9M
YoY Change 8.7% 7.8% -31.3%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$24.72M -$35.03M -$34.33M
YoY Change -1.06% 2.05% 16.12%
Depreciation, Depletion And Amortization $1.671M $1.541M $1.495M
YoY Change 7.05% 3.08% 35.79%
Cash From Operating Activities -$14.50M -$29.31M -$28.42M
YoY Change 13.0% 3.15% 313.59%
INVESTING ACTIVITIES
Capital Expenditures $2.208M $2.588M $1.607M
YoY Change -253.87% 61.05% -37.1%
Acquisitions
YoY Change
Other Investing Activities $13.48M -$22.06M $51.67M
YoY Change -81.2% -142.69% -2.32%
Cash From Investing Activities $11.27M -$24.65M $50.07M
YoY Change -83.96% -149.23% -0.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.122M -2.273M -6.753M
YoY Change 42.88% -66.34% 359.39%
NET CHANGE
Cash From Operating Activities -14.50M -29.31M -28.42M
Cash From Investing Activities 11.27M -24.65M 50.07M
Cash From Financing Activities 4.122M -2.273M -6.753M
Net Change In Cash 894.0K -56.15M 14.76M
YoY Change -98.52% -480.37% -64.8%
FREE CASH FLOW
Cash From Operating Activities -$14.50M -$29.31M -$28.42M
Capital Expenditures $2.208M $2.588M $1.607M
Free Cash Flow -$16.71M -$31.90M -$30.03M
YoY Change 46.59% 6.25% 218.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1270000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
65725000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
78930000
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001444380
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36715
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Nevro Corp.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2568057
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1800 Bridge Parkway
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
251-0005
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
NVRO
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35817154
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64227000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120373000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
277539000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
254012000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
752000
CY2023Q1 us-gaap Inventory Net
InventoryNet
113293000
CY2022Q4 us-gaap Inventory Net
InventoryNet
99638000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14673000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9984000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
535457000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
562937000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22911000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22271000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12341000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13430000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3109000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3164000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
606000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
606000
CY2023Q1 us-gaap Assets
Assets
574424000
CY2022Q4 us-gaap Assets
Assets
602408000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
29229000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
26849000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40367000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
47168000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5323000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5195000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
74919000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
79212000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
187175000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
186867000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8945000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10296000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2157000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2157000
CY2023Q1 us-gaap Liabilities
Liabilities
273196000
CY2022Q4 us-gaap Liabilities
Liabilities
278532000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36376936
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36203423
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35694020
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35520507
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
36000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
945419000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
934132000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2001000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3094000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-642226000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-607197000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
301228000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
323876000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
574424000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
602408000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
96327000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
87842000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
31703000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28750000
CY2023Q1 us-gaap Gross Profit
GrossProfit
64624000
CY2022Q1 us-gaap Gross Profit
GrossProfit
59092000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14755000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12536000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
86192000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
79325000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
100947000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
91861000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36323000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32769000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3278000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
143000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1613000
CY2022Q1 us-gaap Interest Expense
InterestExpense
1603000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-46000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
85000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34704000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34144000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
325000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
181000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35029000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-34325000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
506000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-192000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
587000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1021000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1093000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1213000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33936000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35538000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35584685
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35584685
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35073862
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35073862
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
323876000
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2273000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13561000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35029000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1093000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
301228000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
303616000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
545000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
7298000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13406000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-34325000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1213000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
240386000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-35029000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-34325000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1541000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1495000
CY2023Q1 nvro Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
1088000
CY2022Q1 nvro Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
1008000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
13560000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
13408000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
878000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-449000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
123000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-50000
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
1253000
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
1086000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
308000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
298000
CY2023Q1 nvro Unrealized Gains And Losses On Foreign Currency Translation
UnrealizedGainsAndLossesOnForeignCurrencyTranslation
166000
CY2022Q1 nvro Unrealized Gains And Losses On Foreign Currency Translation
UnrealizedGainsAndLossesOnForeignCurrencyTranslation
-252000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-13132000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7015000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14296000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1919000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4691000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7915000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-61000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2783000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5190000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6752000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6673000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1351000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1198000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29314000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28418000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
54560000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
40226000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
32500000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
91900000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2588000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1607000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24648000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50067000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2273000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
7298000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
545000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2273000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6753000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
89000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-135000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56146000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14761000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
120979000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35316000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64833000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50077000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
358000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
585000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1342000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1342000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are based on historical experience, where applicable, and other assumptions believed to be reasonable by the management. Actual results may differ from those estimates under different assumptions or conditions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic has negatively impacted, and may continue to negatively impact the Company’s operations and revenues and overall financial condition. Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets which could impact the Company’s estimates and assumptions. Changes in the Company’s assessment about the length and severity of the pandemic, as well as other factors, could result in actual results differing from estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-133000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
166000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
128000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-75000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
96327000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
87842000
CY2023Q1 nvro Bad Debt Expense1
BadDebtExpense1
100000
CY2022Q1 nvro Bad Debt Recovery
BadDebtRecovery
100000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M17D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4541000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6201000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2849000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
405000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
417000
CY2023Q1 nvro Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1561000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15974000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1706000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
14268000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12341000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13430000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5323000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5195000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8945000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10296000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
14268000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
15491000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1478000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1375000
CY2023Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
34200000
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
92300000
CY2023Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
8000000.0
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
18600000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
293195000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
17000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
858000
CY2022Q1 nvro Inventory Write Down Cash And Non Cash
InventoryWriteDownCashAndNonCash
1100000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
292354000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
255441000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1436000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
254012000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
283671000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
282818000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
9524000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
9536000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
293195000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
292354000
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
57477000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
53384000
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2551000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1195000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
53265000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
45059000
CY2023Q1 us-gaap Inventory Net
InventoryNet
113293000
CY2022Q4 us-gaap Inventory Net
InventoryNet
99638000
CY2023Q1 nvro Inventory Write Down Cash And Non Cash
InventoryWriteDownCashAndNonCash
1300000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53283000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
51102000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
30372000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28831000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22911000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22271000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1541000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1495000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26490000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
35341000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2877000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1425000
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2974000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1910000
CY2023Q1 nvro Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
235000
CY2022Q4 nvro Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
282000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
2609000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1305000
CY2023Q1 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1147000
CY2022Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
866000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4035000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6039000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40367000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
47168000
CY2021Q2 nvro Additional Operating Lease Right Of Use Asset
AdditionalOperatingLeaseRightOfUseAsset
2900000
CY2021Q2 nvro Additional Operating Lease Liability
AdditionalOperatingLeaseLiability
2900000
CY2023Q1 us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
limited one- to five-year warranty
CY2022Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
866000
CY2021Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
664000
CY2023Q1 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1763000
CY2022Q1 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
715000
CY2023Q1 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
1482000
CY2022Q1 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
927000
CY2023Q1 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1147000
CY2022Q1 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
452000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13560000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13408000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13560000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13408000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35029000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-34325000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35584685
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35584685
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35073862
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35073862
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6624235
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5994757
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2400000
CY2022Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2300000

Files In Submission

Name View Source Status
nvro-20230331_cal.xml Edgar Link unprocessable
0000950170-23-014896-index-headers.html Edgar Link pending
0000950170-23-014896-index.html Edgar Link pending
0000950170-23-014896.txt Edgar Link pending
0000950170-23-014896-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nvro-20230331.htm Edgar Link pending
nvro-20230331.xsd Edgar Link pending
nvro-ex31_1.htm Edgar Link pending
nvro-ex31_2.htm Edgar Link pending
nvro-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
nvro-20230331_def.xml Edgar Link unprocessable
nvro-20230331_lab.xml Edgar Link unprocessable
nvro-20230331_pre.xml Edgar Link unprocessable
nvro-20230331_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending